Company
Board of Directors
 |
Mr. Thomas Everist is Chairman of the Board of Directors of Everist Genomics. He also serves as the President and Chairman of The Everist Company, an aggregate, concrete, and asphalt production company based in Sioux Falls, S.D. Additionally, Mr. Everist is a member of the Board of Directors of MDU Resources Group, Inc., a Fortune 500 company comprised of regulated and nonregulated businesses that sell a broad range of products and services primarily related to supporting energy and transportation infrastructure. He also is a Director of Showplace Wood Products, a Sioux Falls-based custom cabinets manufacturer, and also serves as Chairman of the Board of Directors of Raven Industries, a general manufacturer of electronics, flow controls, and engineered films. Mr. Everist holds a bachelor’s degree in mechanical engineering and a master’s degree in construction management from Stanford University. He is active in the communities in which he resides and currently serves as a director on the Sanford Health Foundation, a non-profit charitable health services organization in Sioux Falls. |
 |
Dr. Prasad Sunkara is an accomplished scientist and serial entrepreneur specializing in the life science sector. He combines over 30 years of management, financing, and R&D experience in therapeutic areas including cancer, cancer supportive care, cardiovascular, metabolic and CNS diseases indications. He is an expert in identifying and licensing compelling technologies, accelerating their preclinical and clinical development in US and India. As a co-founder and CEO of four start-up companies, Dr. Sunkara has a compelling track-record in business development, financing, mergers and acquisitions. In each of these companies (referenced below) he led operational growth and generated financial returns for shareholders which exceeded investor expectations. Dr. Sunkara has also served as a senior executive or board member to seven other companies in the United States and India. His scientific and business-building accomplishments include:
|
 |
Mr. Worzel is co-founder and former CEO of Everist Genomics. In this capacity, he has participated in raising capital, directing R&D activities and building a team of experts to develop, commercialize and market new technologies. In 2010, Mr. Worzel negotiated the purchase of a controlling stake in Angiologix Inc, a company that has developed a novel test for measuring endothelial dysfunction, an early precursor to cardiovascular disease. Under his guidance Everist Genomics has also established ongoing partnerships with several academic institutions both within and outside of Michigan as well as establishing a growing collaboration with the Armed Forces Institute of Pathology, part of the Military Health System. Mr. Worzel has an M.Sc. from the University of Cambridge in computer science and is one of the leading experts in genetics programming. Prior to founding Everist Genomics, Mr. Worzel was the Chief Science Officer at Widevine Technologies, an Internet company based in Seattle, WA. This company has recently been purchased by Google. |
 |
Mr. Randal Charlton’s varied career as an entrepreneur has led him around the world and into the realms of research commercialization in animal, plant and human technology. Prior to joining Everist Genomics in 2005, he co-founded Asterand, a supplier of human tissues for drug discovery and development, in 2000. Under Mr. Charlton’s leadership, Asterand’s operations flourished, developing a global repository of thousands of samples from cooperating hospitals on four continents. The company’s revenues grew from $100,000 to $18 million during Mr. Charlton’s tenure. In 2007, Asterand became a fully public company, and Mr. Charlton stepped down from the company to serve as the executive director of TechTown, the Wayne State University research and technology park. Mr. Charlton began his career as a journalist, winning a number of accolades for his work, including being voted “best agricultural journalist” in Britain at the age of 23. In his late twenties, he became interested in the challenges of commercializing a new technology and decided to transition to a business career. Among his early entrepreneurial success, Mr. Charlton started FarmKey, Ltd. a company specializing in finding new ways to grow food in desert climates, which achieved a multi-million dollar plan backed by the British government to build an agricultural research station at Alexandria University in Egypt. Mr. Charlton holds a BSc in Agriculture from the University of London. |
 |
Mr. Everist attended Stanford University from 1993-1997 and studied Product Design. He worked at Mongo Music, an online music search engine, from 1998 to 2000. Steve was involved from the earliest days of the company with development of search and categorization technology there. MongoMusic sold to Microsoft in 2000 for 65m and became part of MSN Music where he worked until 2001 coding. Steve worked with TeraCloud, an SRM company based in Seattle, for the next year. Steve realized at MongoMusic that his growing interest in Information Science was best served in the Life Sciences. He finished the Stanford Online course offerings in BioInformatics by 2001. Steve spent 2002 sailing from Seattle to Florida via the Panama Canal onboard his 35' sloop StarThrower with his brother Mike. Steve then joined Genetics Squared (now Everist Genomics) in late 2003 where he worked on product development. He has been working with The Everist Company, a 5th generation family business, since 2006 as a director and project manager on several of the companies assets. |
 |
Alex Charlton, Executive Vice-Chairman of the Board of Directors of Everist Genomics, Inc., is an accomplished life science industry business-builder, combining extensive operational experience with investment banking expertise. Among his previous life science roles, Mr. Charlton served as an executive with Eli Lilly, holding various line management positions in sales, marketing, product management and business development (specializing in acquisitions and product licensing). In addition to working in the United States, Mr. Charlton gained valuable experience with Eli Lilly working in the UK, France, Germany, Italy, Spain and the Scandinavian markets. Following 12 years as a life science executive, Mr. Charlton moved to New York to specialize in strategic planning, mergers and acquisitions (M&A), product licensing and structuring commercial partnerships. He was a Principal with Booz Allen Hamilton and subsequently co-founded, and became Chairman of, the New York-headquartered consulting group True North Partners and the advisory group, NorthStar Capital Advisors. Since 1994 Mr. Charlton has led strategic planning, acquisition and licensing transactions for private and public companies in the United States, Europe, and India. He has managed negotiations, conducted due diligence, and helped structure definitive agreements for transactions totaling over $2 billion. Mr. Charlton earned a B.Sc. from Newcastle University, England and an MBA from Cranfield University where he was the recipient of the Booker Prize for Marketing. Mr. Charlton is also the proud recipient of the Gold Duke of Edinburgh Award and is a regular speaker at industry conferences and author of various industry white-papers. |
